Quest Diagnostics (DGX) stock
NYSE
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $28.6B
- As of Nov 13, 2026
- P/E
- 25.29x
- Trailing twelve months
- P/B
- 3.74x
- Latest reported equity
- P/S
- 2.41x
- Trailing twelve months
- ROE
- 14.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $28.6B
- As of Nov 13, 2026
- P/E
- 25.29x
- Trailing twelve months
- P/B
- 3.74x
- Latest reported equity
- P/S
- 2.41x
- Trailing twelve months
- ROE
- 14.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
25.29x
P/B
3.74x
P/S
2.41x
Earnings and dividend metrics▾
Earnings
EPS
$10.26
Earnings per share
BPS
$69.38
Book value per share
ROE
14.8%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $10.26 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $69.38 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 14.8%.
Dividends
Dividend per share
$3.21
Payout ratio
31.3%
Dividend per share and payout ratio are for fiscal 2025.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $321.00 before tax.
- Payout ratio — 31.3% of earnings was paid out as dividends.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 10.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $2.82B+10.0%
$2.49B
Jul–Sep '24
$2.82B
Jul–Sep '25
$3.1B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 23, 2026.
- Earnings per share increased 28.7% from the same quarter a year earlier.
- Revenue increased 10.0% from the same quarter a year earlier.
- Operating income increased 24.1% from the same quarter a year earlier.
- Net income increased 27.3% from the same quarter a year earlier.
Filed Oct 23, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Plewman PatrickSVP for Diagnostic Services · Nov 9, 2026Open-market sale11,717 shares · $3.0MAvg. price $257.34
Show 3 price lots
- 6,793 shares × $257.34$1.7M
- 4,274 shares × $257.34$1.1M
- 650 shares × $257.34$167K
- Plewman PatrickSVP for Diagnostic Services · Nov 9, 2026Option exercise11,067 shares · $1.4MAvg. price $127.7741
Show 2 price lots
- 6,793 shares × $127.805$868K
- 4,274 shares × $127.725$546K
- Doherty Catherine T.Executive Vice President · Nov 3, 2026Open-market sale22,105 shares · $5.5MAvg. price $248.0182
Show 7 price lots
- 5,990 shares × $246.2649$1.5M
- 3,818 shares × $245.4519$937K
- 3,004 shares × $249.4035$749K
- 2,907 shares × $251.2386$730K
- 2,877 shares × $250.4882$721K
- 2,358 shares × $248.3838$586K
- 1,151 shares × $246.9835$284K
- Doherty Catherine T.Executive Vice President · Nov 3, 2026Option exercise22,105 shares · $2.7MAvg. price $121.80594,054 shares held after
- DELANEY MARK ESVP & Chief Commercial Officer · Nov 3, 2026Grant or award2,615 shares · $0Avg. price $012,975 shares held after
- Doherty Catherine T.Executive Vice President · Nov 3, 2026Grant or award4,827 shares · $0Avg. price $071,949 shares held after
- Ramachandran SubuSVP, Regional Businesses · Nov 3, 2026Grant or award352 shares · $0Avg. price $02,832 shares held after
- PFEIFFER GARY MDirector · Oct 26, 2026Open-market sale1,203 shares · $292KAvg. price $24329,802 shares held after
- SAMAD SAMExecutive Vice President & CFO · Oct 21, 2026Grant or award90 shares · $21KAvg. price $235.93933,568 shares held after
- Gregg Vicky BDirector · Oct 21, 2026Grant or award63 shares · $15KAvg. price $235.93918,449 shares held after
- Plewman PatrickSVP for Diagnostic Services · Oct 21, 2026Other41 shares · $10KAvg. price $235.9415,334 shares held after
- KUPPUSAMY KARTHIKSVP, Clinical Solutions · Oct 21, 2026Other33 shares · $8KAvg. price $235.943913,619 shares held after
- DELANEY MARK ESVP & Chief Commercial Officer · Oct 21, 2026Other25 shares · $6KAvg. price $235.941210,360 shares held after
- MAIN TIMOTHY LDirector · Oct 21, 2026Other18 shares · $4KAvg. price $235.937222,478 shares held after
- CARTER ROBERT BDirector · Oct 21, 2026Other10 shares · $2KAvg. price $235.933,874 shares held after
- Lassiter Wright IIIDirector · Oct 21, 2026Other6 shares · $1KAvg. price $235.958310,329 shares held after
- Davis J. E.CEO and President · Sep 1, 2026Open-market sale10,000 shares · $2.4MAvg. price $242.72122,423 shares held after
- PREVOZNIK MICHAEL ESVP & General Counsel · Aug 28, 2026Open-market sale22,677 shares · $5.5MAvg. price $243.1134
Show 3 price lots
- 16,010 shares × $242.8755$3.9M
- 6,237 shares × $243.6275$1.5M
- 430 shares × $244.5148$105K
- PREVOZNIK MICHAEL ESVP & General Counsel · Aug 28, 2026Option exercise22,677 shares · $2.5MAvg. price $112.1760,234 shares held after
- PREVOZNIK MICHAEL ESVP & General Counsel · Aug 28, 2026Gift1,000 shares · $0Avg. price $036,557 shares held after
- DELANEY MARK ESVP & Chief Commercial Officer · Jul 28, 2026Open-market sale1,600 shares · $376KAvg. price $235.1810,335 shares held after
- SAMAD SAMExecutive Vice President & CFO · Jul 22, 2026Grant or award102 shares · $21KAvg. price $206.80733,478 shares held after
- Gregg Vicky BDirector · Jul 22, 2026Grant or award72 shares · $15KAvg. price $206.808118,386 shares held after
- Plewman PatrickSVP for Diagnostic Services · Jul 22, 2026Other46 shares · $10KAvg. price $206.80715,293 shares held after
- KUPPUSAMY KARTHIKSVP, Clinical Solutions · Jul 22, 2026Other37 shares · $8KAvg. price $206.80713,557 shares held after
- DELANEY MARK ESVP & Chief Commercial Officer · Jul 22, 2026Other34 shares · $7KAvg. price $206.807111,935 shares held after
- MAIN TIMOTHY LDirector · Jul 22, 2026Other21 shares · $4KAvg. price $206.8122,460 shares held after
- CARTER ROBERT BDirector · Jul 22, 2026Other11 shares · $2KAvg. price $206.80363,864 shares held after
- Lassiter Wright IIIDirector · Jul 22, 2026Other6 shares · $1KAvg. price $206.813310,323 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QQuest Diagnostics said net revenues for the 3-month period ended September 30, 2026 increased 10.0% from the prior-year period, with DIS revenues up 10.2%, DIS volume up 14.5%, and revenue per requisition down 4.2%.Published Oct 23, 2026 · Filed Oct 23, 2026Read the summary →
- AI summary8-KQuest Diagnostics announced on October 6, 2026 that Catherine T. Doherty will retire in July 2027.Published Oct 6, 2026 · Filed Oct 6, 2026Read the summary →
- AI summary8-KQuest Diagnostics said on April 27, 2026 it priced a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 under its shelf registration statement.Published Oct 2, 2026 · Filed May 1, 2026Read the summary →
- Quest Diagnostics said net revenues for the 3-month period ended September 30, 2026 increased 10.0% from the prior-year period, with DIS revenues up 10.2%, DIS volume up 14.5%, and revenue per requisition down 4.2%.Read the full analysis →
- Quest Diagnostics announced on October 6, 2026 that Catherine T. Doherty will retire in July 2027.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Quest Diagnostics (DGX) stock information
NYSE
Quest Diagnostics (DGX) is listed on NYSE. Its market capitalization is about $28.6B. On trailing-twelve-month earnings the P/E ratio is 25.29, and the P/B ratio is 3.74. Return on equity is 14.8%. These figures are computed in-house from official filings and are reference information only.
Quest Diagnostics — frequently asked questions
- What is the P/E ratio of Quest Diagnostics (DGX)?
- On a trailing-twelve-month basis, DGX trades at a P/E ratio of 25.29. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Quest Diagnostics?
- DGX has a market capitalization of about $28.6B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.